Brief Summary: This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive…...
VF Board of Directors Welcomes Caz Cazanov
In March 2019 we published a story about Caz Cazanov and her personal experience with vasculitis. After being diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA) in 2017, Caz was treated with high-dose steroids and cyclophosphamide infusions, and spent three weeks in the hospital and in a multidisciplinary rehabilitation facility. She…...
FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES)
Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases Issued: 25 September 2020, London UK GlaxoSmithKline plc (GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12…...
VF Congratulates 2019 V-RED Winners, Program Participation Soars in Sixth Year
Two winners tied for first place and another received an honorable mention in the Vasculitis Foundation’s 2019 Recognizing Excellence in Diagnostics (V-RED) award program. With more nominations than ever before, the program, now in its sixth year, has grown into a powerful campaign that raises awareness about early diagnosis. Mark…...
- 1
- 2
